Blood biomarkers may replace risky biopsies for brain tumor patients

NCT ID NCT06104930

Recruiting now Knowledge-focused Sponsor: University Hospital Heidelberg Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at tiny particles in the blood (extracellular vesicles) from 60 meningioma patients who have had radiotherapy. The goal is to see if these particles can act as a 'liquid biopsy' to monitor the tumor and predict outcomes without needing a surgical biopsy. Researchers will track changes in these particles over time and compare them to tumor progression and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to monitor meningioma and guide treatment decisions without needing repeated biopsies.
What could go wrong: This is an early exploratory study with only 60 participants, so results may not be conclusive or widely applicable. The biomarker approach is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGIOMA

Contacts and locations

Locations

University Hospital of Heidelberg, Radiation Oncology
RECRUITING

Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.